Jeuveau vs Botox: What the Head-to-Head Trial Actually Showed, and What It Costs in Wisconsin
If you have been quoted Jeuveau instead of Botox lately, you are seeing a genuine shift in the injectables market rather than a sales tactic. Jeuveau has grown fast, it is usually cheaper per unit, and in the largest head-to-head study ever run on frown lines it held its own against Botox. What it did not do is beat Botox, and anyone telling you otherwise is selling. Here is what the evidence actually says, what both cost in Wisconsin, who makes them, and how to pick. If you already know you want it, our Jeuveau page has the pricing and booking.
They are the same kind of drug, made by different companies
Both Jeuveau and Botox are botulinum toxin type A. Injected into a muscle, they block the signal that tells it to contract, so the skin above stops creasing every time you frown. That mechanism is identical. What differs is the manufacturer, the purification process, and the accessory proteins packaged around the active molecule.
We carry both, so this is not a pitch for one over the other: see Jeuveau and Botox for what each costs here. Botox Cosmetic is onabotulinumtoxinA, made by Allergan Aesthetics, now part of AbbVie. It has been FDA approved for cosmetic use since 2002 and is the most studied neurotoxin in the world. Jeuveau is prabotulinumtoxinA-xvfs, developed and manufactured by Daewoong Pharmaceutical in South Korea and licensed to Evolus for aesthetic distribution in the United States. It was FDA approved in February 2019.
Because they are different drugs, units are not automatically interchangeable between brands. Jeuveau and Botox happen to dose roughly one to one, which is why a quote in units reads the same on either. Dysport does not: it uses a different unit scale entirely, so a Dysport quote in units will look much larger for the same result.
What the head-to-head trial actually found
The EVOLUTION study is the largest head-to-head phase III trial ever run comparing two neurotoxins on frown lines. It was randomised, double blind and placebo controlled, and it compared a single dose of Jeuveau against a single dose of Botox.
At the primary endpoint, 87.2 percent of the Jeuveau group responded, against 82.8 percent of the Botox group and 4.2 percent on placebo. On the face of it that is a 4.4 point edge to Jeuveau. The confidence interval around that difference ran from minus 1.9 to plus 10.8, which crosses zero, so the result does not show Jeuveau is better. It shows the two are statistically equivalent.
That is a genuinely good result and it is worth understanding precisely. Non-inferiority means Jeuveau cleared the bar of performing as well as the most established product in the category. It does not mean it outperforms it. If a clinic tells you Jeuveau is stronger, more precise or longer lasting than Botox, ask them which study says so.
The 4.4 point gap between the two active arms carried a 95% confidence interval of -1.9 to +10.8. Because that range includes zero, the trial concluded non-inferiority, not superiority. Both vastly outperformed placebo.
Onset and duration: where the real differences are, and are not
Onset is the one place Jeuveau may have a modest edge. In European and Canadian data, 54 percent of patients saw visible change by day two, with most reaching full effect around day 30. Botox is usually described as starting to work in three to five days with full effect at two weeks. In practice the difference between the two is small, and how quickly you personally respond varies more than the brands do.
Duration is where the marketing gets loose. Both products last roughly three to four months for most people. There is no credible evidence that Jeuveau outlasts Botox. The phrase half life gets used in advertising copy, but it is not how these drugs are measured. What matters is how long muscle function stays reduced, and on that measure the two are comparable.
If duration is genuinely your priority, the product with a real claim to longer effect is Daxxify from Revance, which uses a peptide carrier and has reported longer intervals in trials. It also costs more. That is a different conversation from Jeuveau versus Botox. If what is bothering you is volume loss rather than movement, the answer is not tox at all, it is dermal filler or facial balancing.
| Brand | Molecule | Maker | FDA cosmetic approval | Typical duration |
|---|---|---|---|---|
| Botox Cosmetic | onabotulinumtoxinA | Allergan Aesthetics (AbbVie) | Frown, crow's feet, forehead | 3 to 4 months |
| Jeuveau | prabotulinumtoxinA-xvfs | Daewoong, distributed by Evolus | Frown lines only | 3 to 4 months |
| Dysport | abobotulinumtoxinA | Galderma / Ipsen | Frown lines | 3 to 4 months |
| Xeomin | incobotulinumtoxinA | Merz Aesthetics | Frown lines | 3 to 4 months |
| Daxxify | daxibotulinumtoxinA | Revance | Frown lines | Reported longer in trials |
Dysport uses a different unit scale, so its unit counts are not comparable to the others. Always compare the price of a finished treatment, not the price of a unit, when crossing brands.
Price is the real difference, and it is not small
This is where Jeuveau genuinely separates itself. Across the United States Jeuveau typically runs 8 to 16 dollars a unit while Botox runs 10 to 20. Clinic to clinic the gap is usually 20 to 30 percent for an equivalent result, because the units dose one to one.
On a treatment that takes 20 units, a two dollar difference per unit is 40 dollars. On a 40 unit treatment three or four times a year, the same gap is a few hundred dollars annually. That is the entire reason Jeuveau has grown: not that it works better, but that it works the same for less.
Bars are drawn at the midpoint of each national range. Raw Glo charges a flat $11 per unit, which sits at the low end of the Wisconsin market for either product.
What it costs around Waukesha
Wisconsin pricing sits a little below the national average. Statewide, tox generally runs 10 to 14 dollars a unit, and several Milwaukee-area clinics advertise 10 or 11 dollars. We charge 11 dollars a unit and tell you the unit count before anything is injected, so you know the total in advance rather than at checkout.
The number that actually matters is the finished treatment, because unit counts vary by muscle strength and by the area treated. A light first treatment on the elevens is a very different bill from a full upper face. Full pricing sits on the Jeuveau and Botox pages, and the lip flip is priced there too.
| Area treated | Typical units | Cost at Raw Glo | Roughly how often |
|---|---|---|---|
| Frown lines (the elevens) | 20 to 25 | $220 to $275 | Every 3 to 4 months |
| Forehead lines | 10 to 20 | $110 to $220 | Every 3 to 4 months |
| Crow's feet, both sides | 12 to 24 | $132 to $264 | Every 3 to 4 months |
| Lip flip | 4 to 6 | $44 to $66, or $100 booked alone | Every 2 to 3 months |
| Full upper face | 40 to 60 | $440 to $660 | Every 3 to 4 months |
| Underarm sweating | Fixed treatment | $950 | Every 6 to 12 months |
Unit ranges are typical, not a quote. Your injector maps your muscles first and confirms the count and the total before treating. Prices current as of October 2026.
Who is actually behind each brand
Botox belongs to Allergan Aesthetics, a division of AbbVie, one of the largest pharmaceutical companies in the world. That scale buys enormous clinical evidence, reliable supply and the Alle loyalty programme, where accumulated points convert into treatment credit. Botox still holds roughly 60 percent of the US toxin market.
Jeuveau is the product of a partnership. Daewoong Pharmaceutical, a major South Korean manufacturer, developed and makes the toxin. Evolus, a Nasdaq-listed company led by chief executive David Moatazedi, licenses it for aesthetic distribution in the United States and runs the brand. Evolus deliberately positions itself as a cash-pay performance beauty company rather than a traditional pharma business, which is why its pricing and its rewards programme look more like consumer retail.
That partnership has a litigious history worth knowing about. A trade secret dispute involving Medytox, Daewoong and the US International Trade Commission disrupted Jeuveau's early years before being settled. Supply has been stable since, but it is part of the brand's story.
| Jeuveau | Botox Cosmetic | |
|---|---|---|
| Brand owner | Evolus (Nasdaq: EOLS) | Allergan Aesthetics, an AbbVie company |
| Manufacturer | Daewoong Pharmaceutical, South Korea | Allergan, United States and Ireland |
| Leadership | David Moatazedi, chief executive | Part of AbbVie's aesthetics division |
| US launch | 2019 | 2002 for cosmetic use |
| Loyalty programme | Evolus Rewards, $40 off every 90 days | Alle, points convert to treatment credit |
| US market position | Fast-growing challenger | Category leader, around 60% share |
Is Jeuveau really taking share?
Yes, and the numbers are public. Evolus finished 2025 with about 297 million dollars in revenue and guided 2026 to between 327 and 337 million. Second quarter 2026 revenue came in at 84.1 million, up 21 percent year over year, with the company reporting share gains across injectable aesthetics and a third consecutive quarter of positive adjusted earnings. Its rewards programme passed a million enrolled consumers.
What that does not mean is that Botox is finished. A 60 percent share in a growing market is still dominant, and AbbVie has responded with pricing moves and loyalty incentives of its own. The accurate picture is a market that used to be one brand and is now genuinely competitive, which is good for you as the person paying.
Guidance bar drawn at the midpoint of the range. Source: Evolus investor reporting, 2026.
How to actually choose between them
If you have read this far and the money case is what interests you, we go deeper on it in why Jeuveau is better than Botox. The uncomfortable truth in all of this is that the brand on the vial is a smaller variable than who is holding the syringe. Dose placement, muscle mapping and knowing when to stop account for more of your result than the choice between two drugs that performed equivalently in a trial of several hundred people.
- Budget matters most to you: Jeuveau, nearly always. Same unit maths, lower price per unit, and a rewards programme that takes $40 off every 90 days.
- You are treating only the elevens: Either. This is the one area where Jeuveau carries a full FDA cosmetic approval, so the evidence is directly on point.
- You are treating forehead or crow's feet: Botox has on-label approval for both. Jeuveau is used there off-label. Many injectors do it routinely and well, but if being on-label matters to you, that is the honest distinction.
- You have had a poor result with one brand: Switching is reasonable. Individual response varies, and some people genuinely do better on one formulation.
- Duration is your single priority: Neither. Look at Daxxify and expect to pay more for it.
- You are brand new to tox: Start conservative on either one. The product matters far less than the injector's restraint on your first visit.
How we handle it at Raw Glo
We charge 11 dollars a unit and we tell you the count before we treat, so there is no arithmetic surprise afterwards. We are conservative on a first appointment on purpose, because adding more at a two-week check is easy and taking it away is not possible.
If you are deciding between brands, say so at your consultation and we will talk through it honestly, including the cases where we think the cheaper option is the right one and the cases where it is not. Our cosmetic nurses map where your muscles actually pull before dosing, which is the part that decides whether you look rested or obviously treated.
Book a consultation and we will plan it properly, with no pressure and no package you have to be talked into. You can see pricing and book on the Jeuveau page, or call us if you would rather talk it through first.
Frequently asked questions
Is Jeuveau just a cheaper copy of Botox?
No. It is a separate drug with its own FDA approval and its own manufacturing process, made by Daewoong in South Korea. It is not a generic or a biosimilar, because biologics like these cannot be copied the way a small-molecule drug can. It is a competitor that happens to cost less.
Do Jeuveau and Botox units mean the same thing?
For these two, yes, they dose roughly one to one, so a 20 unit treatment is comparable on either. That is not true across all brands. Dysport uses a different unit scale, so comparing its unit price to Botox is meaningless. Compare the finished treatment price instead.
Does Jeuveau last longer than Botox?
No. Both last roughly three to four months for most people and no credible head-to-head data shows Jeuveau outlasting Botox. If longer duration is your goal, Daxxify is the product with an actual claim to it, at a higher price.
Is Jeuveau safe?
It carries the same safety profile and the same boxed warning about toxin spread as every botulinum toxin product, and it cleared FDA review in 2019. The risks are the same ones that apply to Botox: temporary bruising, headache, and occasionally a droopy eyelid if product migrates, which is why injector skill matters.
Can I switch from Botox to Jeuveau?
Yes, and plenty of people do. There is no washout period needed. Just tell your injector what you have had before, roughly how many units, and whether you were happy with the result, so they can match or adjust the dose.
Why do some clinics only carry one brand?
Volume pricing. Committing to a single manufacturer earns better per-vial pricing and loyalty programme support, which some clinics pass on and some keep. It is worth asking whether a clinic recommends a brand because it suits you or because it is the only one in the fridge.
What does tox cost in Waukesha?
We charge $11 per unit. Wisconsin generally runs $10 to $14, which is slightly below the national average of $10 to $20 for Botox and $8 to $16 for Jeuveau. A typical frown line treatment of 20 to 25 units works out to $220 to $275 here.
How do I know how many units I need?
Your injector decides after looking at how your muscles actually move, not from a chart. Stronger muscles need more. First-timers usually get less than they expect, deliberately, so there is room to add at a two-week follow-up.
This article is general information, not medical advice. Your provider will tailor any plan to your health history and goals during a consultation.
